Microsoft Confirms Call Of Duty: Black Ops 6 On Xbox Game Pass At Launch
Microsoft confirms Call of Duty: Black Ops 6 will launch on Xbox Game Pass and retail versions. Pre-install starts June 9.
Dogecoin Is ‘The Easiest Play, ‘Will 2x Instantly’ Once It Starts Moving, Bullish Traders Predict
Dogecoin (CRYPTO: DOGE) has caught the attention of cryptocurrency traders, who see the apex meme coin poised for upside soon.
Roblox Stock Faces Death Cross As Mixed Earnings, Downgraded Outlook Signal Trouble Ahead
Roth MKM's Eric Handler reduced the price target for Roblox from $55 to $35 while the technical outlook for the stock has turned bearish.
Volatility Spooks Investors As Treasury Yields, Dollar Climb Ahead Of Key Economic Releases: What’s Driving Markets Wednesday?
Volatility surged back into the market on Wednesday, with the CBOE Volatility Index (VIX) spiking 9% after hitting nearly three-year lows last week, fueled by fresh upticks in Treasury bond yields.
Cava Group In The Sweet Spot? CEO Sees Consumers Trading Down From Casual Dining, Trading Up From Fast Food: ‘We Don’t Think It’s An Either Or’
CAVA Group turned in better-than-expected earnings results for the first quarter late Tuesday.
Magnificent 7 Hits 31% Weighting for S&P 500, Top 5 Holdings Hit 27% Weighting: Will Investors Look Elsewhere?
The Magnificent 7 stocks make up 31% of the S&P 500, which is the highest weighting realized in years.
Wall Street Moves From T+2 To T+1 Settlement: How It Could Affect Investments, Trading, Tax Decisions
T+1 settlement system shortens transaction cycle, reducing risk and increasing efficiency. Charles Schwab shares insights on its impact and challenges.
Bitcoin’s New All-Time High Depends On This Macro Indicator: 10x Research
Bitcoin‘s (CRYPTO: BTC) rise to new highs may depend on a single data point—inflation—according to a new report by crypto research firm 10x
Johnson & Johnson’s Drug Seltorexant Aces Late-Stage Depression Trial
Johnson & Johnson reported successful Phase 3 trial results for seltorexant, an investigational treatment for major depressive disorder with insomnia.
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca’s Drug
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.